- Home
- BOLD vs IOBT Comparison
BOLD vs IOBT Comparison
Compare BOLD & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | IOBT |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 26.6M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BOLD | IOBT |
|---|---|---|
| Price | $1.12 | $0.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $4.00 | $2.25 |
| AVG Volume (30 Days) | 63.7K | ★ 890.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | 26.77 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.21 |
| 52 Week High | $1.78 | $2.79 |
Technical Indicators
Market Signals| Indicator | BOLD | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 25.94 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.20 | $0.40 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.92 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.